Vanguard Asset Management
RPRX icon

Vanguard Asset Management’s Royalty Pharma RPRX Stock Holding History

Vanguard Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.3M Buy
932,544
+126,399
+16% +$6.58M 0.04% 397
2026
Q1 		$38.7M Buy
+806,145
New +$35.3M 0.03% 426

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CIA
Caledonia Investments (Australia) Sydney NSW, Australia $2.93B AUM 37.21% 1-Year Est. Return

Vanguard Asset Management's RPRX Position: Q2 2026 in Review

Vanguard Asset Management increased its Royalty Pharma (RPRX) stake by 16% in Q2 2026, buying an estimated $6.58M and bringing the position to 932,544 shares worth $52.3M. The position accounts for 0.04% of the portfolio, ranked #397.

Vanguard Asset Management first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 607 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Vanguard Asset Management held 932,544 shares of Royalty Pharma worth $52.3M as of Q2 2026.
  • Vanguard Asset Management bought 126,399 Royalty Pharma shares in Q2 2026, an estimated $6.58M.
  • Royalty Pharma made up 0.04% of Vanguard Asset Management's portfolio in Q2 2026, its #397 holding.
  • Vanguard Asset Management first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 607 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.